المؤلفون: N. V. Pizova, A. V. Pizov, I. N. Solovyov

المصدر: Медицинский совет, Vol 0, Iss 11, Pp 62-70 (2022)

مصطلحات موضوعية: insomnia, risk factors, sex- and age-specific features, comorbidity, therapy, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/6957; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/864648b09a4c4149bcac37d3c884bd7a

المؤلفون: Yu. S. Filatova, I. N. Solovyov

المصدر: Медицинский совет, Vol 0, Iss 2, Pp 86-93 (2021)

مصطلحات موضوعية: osteoarthritis: knee joints, intra-articular injections, symptomatic slow-acting drugs, ultrasound of the musculoskeletal system, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/6016; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/df7c21a3c5024a5fb2f3adaeeb710094

المؤلفون: Yu. S. Filatova, I. N. Solovyov

المصدر: Медицинский совет, Vol 0, Iss 19, Pp 89-97 (2020)

مصطلحات موضوعية: osteoarthritis, hyaluronic acid, joint management of a patient with osteoarthritis, intra-articular administration, comorbidity, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/5923; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/ea0e682c518942dfb267f5428d708b4a

المؤلفون: Y. S. Filatova, I. N. Solovyov, A. M. Gruzdev, V. V. Bobyleva, Ю. С. Филатова, И. Н. Соловьев, А. М. Груздев, В. В. Бобылева

المصدر: Meditsinskiy sovet = Medical Council; № 3 (2024); 150-157 ; Медицинский Совет; № 3 (2024); 150-157 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: синергизм терапии, COVID-19, diagnosis, femoral head aseptic necrosis, magnetic resonance imaging, osseinhydroxyapatite complex, chondroitin sulfate, synergism of therapy, диагностика, асептический некроз головки бедренной кости, магнитнорезонансная томография, оссеин-гидроксиапатитный комплекс, хондроитина сульфат

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8204/7224; Dubois EL, Cozen L. Avascular (aseptic) bone necrosis associated with systemic lupus erythematosus. JAMA. 1960;174:966–971. https://doi.org/10.1001/jama.1960.03030080028005.; Dhillon M, Kumar V, Kumar P. Avascular Necrosis of the Hip: Historical Perspective. In: Kumar P, Aggarwal, S, Kumar V (eds.). Insights into Avascular Necrosis of the Femoral Head. Singapore: Springer; 2023, pp. 13–21. https://doi.org/10.1007/978-981-99-1346-6_2.; Mont MA, Salem HS, Piuzzi NS, Goodman SB, Jones LC. Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today?: A 5-Year Update. J Bone Joint Surg Am. 2020;102(12):1084–1099. https://doi.org/10.2106/JBJS.19.01271.; Björkman A, Svensson PJ, Hillarp A, Burtscher IM, Rünow A, Benoni G. Factor V leiden and prothrombin gene mutation: risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res. 2004;(425):168–172. https://doi.org/10.1097/00003086-200408000-00023.; Zalavras CG, Vartholomatos G, Dokou E, Malizos KN. Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin Orthop Relat Res. 2004;(422):251–255. Available at: https://pubmed.ncbi.nlm.nih.gov/15187864/.; Glueck CJ, Freiberg RA, Fontaine RN, Tracy T, Wang P. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res. 2001;(386):19–33. https://doi.org/10.1097/00003086-200105000-00004.; Kim TH, Hong JM, Lee JY, Oh B, Park EK, Lee CK et al. Promoter polymorphisms of the vascular endothelial growth factor gene is associated with an osteonecrosis of the femoral head in the Korean population. Osteoarthritis Cartilage. 2008;16(3):287–291. https://doi.org/10.1016/j.joca.2007.06.017.; Rueda JC, Duque MA, Mantilla RD, Iglesias-Gamarra A. Osteonecrosis and antiphospholipid syndrome. J Clin Rheumatol. 2009;15(3):130–132. https://doi.org/10.1097/RHU.0b013e31819dbd20.; Li H, Zhang J, He JW, Wang K, Wang GS, Jiang N et al. Symptomatic osteonecrosis of the femoral head after adult orthotopic liver transplantation. Chin Med J (Engl). 2012;125(14):2422–2426. https://doi.org/10.3760/cma.j.issn.0366-6999.2012.14.004.; Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O et al. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int. 2012;32(1):177–182. https://doi.org/10.1007/s00296-010-1597-9.; Varoga D, Drescher W, Pufe M, Groth G, Pufe T. Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head. Clin Orthop Relat Res. 2009;467(12):3273–3282. https://doi.org/10.1007/s11999-009-1076-3.; Lewington MR, El-Hawary R. Legg-Calve-Perthes disease in a patient with Albright hereditary osteodystrophy: a case report. J Bone Joint Surg Am. 2010;92(2):450–455. https://doi.org/10.2106/JBJS.I.00153.; Aya-ay J, Athavale S, Morgan-Bagley S, Bian H, Bauss F, Kim HK. Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head. J Bone Miner Res. 2007;22(1):93–100. https://doi.org/10.1359/jbmr.060817.; Kim HK, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis. J Bone Miner Res. 2006;21(12):1946–1954. https://doi.org/10.1359/jbmr.060905.; Yang J, Wang L, Xu Y, Fan K, Wang J. An experimental osteonecrosis of femoral head induced by a combination of a single low-dose lipopolysaccharide and methylprednisone. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2008;22(3):271–275. (In Chinese) Available at: https://pubmed.ncbi.nlm.nih.gov/18396701/.; Steffen RT, Athanasou NA, Gill HS, Murray DW. Avascular necrosis associated with fracture of the femoral neck after hip resurfacing: histological assessment of femoral bone from retrieval specimens. J Bone Joint Surg Br. 2010;92(6):787–793. https://doi.org/10.1302/0301-620X.92B6.23377.; Смирнов АВ. Дифференциальная рентгенологическая диагностика изменений в суставах кистей и дистальных отделов стоп при ревматических заболеваниях. Современная ревматология. 2010;4(4):83–88. https://doi.org/10.14412/1996-7012-2010-643.; Hungerford DS, Lennox DW. The importance of increased intraosseous pressure in the development of osteonecrosis of the femoral head: implications for treatment. Orthop Clin North Am. 1985;16(4):635–654. https://doi.org/10.1016/S0030-5898(20)30432-6.; Ugwonali OF, Sarkissian H, Nercessian OA. Bilateral osteonecrosis of the femoral head associated with pregnancy: four new cases and a review of the literature. Orthopedics. 2008;31(2):183. https://doi.org/10.3928/01477447-20080201-36.; Mont MA, Cherian JJ, Sierra RJ, Jones LC, Lieberman JR. Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today? A TenYear Update. J Bone Joint Surg Am. 2015;97(19):1604–1627. https://doi.org/10.2106/JBJS.O.00071.; Kang JS, Park S, Song JH, Jung YY, Cho MR, Rhyu KH. Prevalence of osteonecrosis of the femoral head: a nationwide epidemiologic analysis in Korea. J Arthroplasty. 2009;24(8):1178–1183. https://doi.org/10.1016/j.arth.2009.05.022.; Ikeuchi K, Hasegawa Y, Seki T, Takegami Y, Amano T, Ishiguro N. Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan. Mod Rheumatol. 2015;25(2):278–281. https://doi.org/10.3109/14397595.2014.932038.; Zhao DW, Yu M, Hu K, Wang W, Yang L, Wang BJ et al. Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population: Results from a Nationally Representative Survey. Chin Med J (Engl). 2015;128(21):2843–2850. https://doi.org/10.4103/0366-6999.168017.; Торгашин АН, Родионова СС, Шумский АА, Макаров МА, Торгашина АВ, Ахтямов ИФ и др. Лечение асептического некроза головки бедренной кости. Клинические рекомендации. Научно-практическая ревматология. 2020;58(6):637–645. https://doi.org/10.47360/1995-4484-2020-637-645; Liu J, Li S, Liu J, Liang B, Wang X, Wang H et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. https://doi.org/10.1016/j.ebiom.2020.102763.; Shen J, Liang BL, Zeng QS, Chen JY, Liu QY, Chen RC, Zhong NS. Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou. Zhonghua Yi Xue Za Zhi. 2004;84(21):1814–1817. (In Chinese) Available at: https://rs.yiigle.com/cmaid/109604.; Sinha PR, Mallick N, Sahu RL. Avascular Necrosis of the Hip after the COVID-19 Pandemic. J Pharm Bioallied Sci. 2023;15(Suppl. 1):S661– S664. https://doi.org/10.4103/jpbs.jpbs_87_23.; Koo KH, Mont MA, Cui Q, Hines JT, Yoon BH, Novicoff WM et al. The 2021 Association Research Circulation Osseous Classification for EarlyStage Osteonecrosis of the Femoral Head to Computed Tomography-Based Study. J Arthroplasty. 2022;37(6):1074–1082. https://doi.org/10.1016/j.arth.2022.02.009.; Dhanasekararaja P, Soundarrajan D, Kumar KS, Pushpa BT, Rajkumar N, Rajasekaran S. Aggressive Presentation and Rapid Progression of Osteonecrosis of the Femoral Head After COVID-19. Indian J Orthop. 2022;56(7):1259–1267. https://doi.org/10.1007/s43465-022-00635-2.; Dolat Abadi H, Parsa A, Stelzer J, Anz A, Ebrahimzadeh MH, Bagheri F et al. Screening for Femoral Head Osteonecrosis Following COVID-19: Is It Worth It? Arch Bone Jt Surg. 2023;11(12):731–737. https://doi.org/10.22038/ABJS.2023.73742.3414.; Ito H, Matsuno T, Minami A. Relationship between bone marrow edema and development of symptoms in patients with osteonecrosis of the femoral head. AJR Am J Roentgenol. 2006;186(6):1761–1770. https://doi.org/10.2214/AJR.05.0086.; Pivec R, Johnson AJ, Harwin SF, Mont MA. Differentiation, diagnosis, and treatment of osteoarthritis, osteonecrosis, and rapidly progressive osteoarthritis. Orthopedics. 2013;36(2):118–125. https://doi.org/10.3928/01477447-20130122-04.; Tripathy SK, Goyal T, Sen RK. Management of femoral head osteonecrosis: Current concepts. Indian J Orthop. 2015;49(1):28–45. https://doi.org/10.4103/0019-5413.143911.; Petek D, Hannouche D, Suva D. Osteonecrosis of the femoral head: pathophysiology and current concepts of treatment. EFORT Open Rev. 2019;4(3):85–97. https://doi.org/10.1302/2058-5241.4.180036.; Chotanaphuti T, Thongprasert S, Laoruengthana A. Low molecular weight heparin prevents the progression of precollapse osteonecrosis of the hip. J Med Assoc Thai. 2013;96(10):1326–1330. Available at: https://pubmed.ncbi.nlm.nih.gov/24350415/.; Agarwala S, Shetty V, Karumuri LK, Vijayvargiya M. Patellar Resurfacing versus Nonresurfacing with Patellaplasty in Total Knee Arthroplasty. Indian J Orthop. 2018;52(4):393–398. https://doi.org/10.4103/ortho.IJOrtho_512_16.; Lee YK, Ha YC, Cho YJ, Suh KT, Kim SY, Won YY et al. Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis? A Prospective, Randomized, Open-Label, Multicenter Study. J Bone Joint Surg Am. 2015;97(14):1142–1148. https://doi.org/10.2106/JBJS.N.01157.; Albers A, Carli A, Routy B, Harvey EJ, Séguin C. Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study. Can J Surg. 2015;58(3):198–205. https://doi.org/10.1503/cjs.016814.; Claßen T, Becker A, Landgraeber S, Haversath M, Li X, Zilkens C et al. Long-term Clinical Results after Iloprost Treatment for Bone Marrow Edema and Avascular Necrosis. Orthop Rev (Pavia). 2016;8(1):6150. https://doi.org/10.4081/or.2016.6150.; Родионова СС, Колондаев АФ, Соколов ВА, Марков СА. Опыт применения остеогенона в травматологии и ортопедии. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2022;8(4):41–45. https://doi.org/10.17816/vto100413.; Heaney RP. Quantifying human calcium absorption using pharmacokinetic methods. J Nutr. 2003;133(4):1224–1226. https://doi.org/10.1093/jn/133.4.1224.; Buclin T, Jacquet AF, Burckhardt P. Absorption intestinale de gluconate de calcium et de complexe osséino-minéral: évaluation par des dosages conventionnels. Schweiz Med Wochenschr. 1986;116(50):1780–1783. Available at: https://pubmed.ncbi.nlm.nih.gov/3026039/.; Fernández-Pareja A, Hernández-Blanco E, Pérez-Maceda JM, Riera Rubio VJ, Palazuelos JH, Dalmau JM. Prevention of osteoporosis: four-year follow-up of a cohort of postmenopausal women treated with an ossein-hydroxyapatite compound. Clin Drug Investig. 2007;27(4):227–232. https://doi.org/10.2165/00044011-200727040-00001.; Castelo-Branco C, Ciria-Recasens M, Cancelo-Hidalgo MJ, Palacios S, Haya-Palazuelos J, Carbonell-Abelló J et al. Efficacy of osseinhydroxyapatite complex compared with calcium carbonate to prevent bone loss: a meta-analysis. Menopause. 2009;16(5):984–991. https://doi.org/10.1097/gme.0b013e3181a1824e.; Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int. 2013;24(2):567–580. https://doi.org/10.1007/s00198-012-2224-2.; Michaëlsson K, Melhus H, Warensjö Lemming E, Wolk A, Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ. 2013;346:f228. https://doi.org/10.1136/bmj.f228.; Sung PH, Yang YH, Chiang HJ, Chiang JY, Chen CJ, Yip HK, Lee MS. Cardiovascular and Cerebrovascular Events Are Associated With Nontraumatic Osteonecrosis of the Femoral Head. Clin Orthop Relat Res. 2018;476(4):865–874. https://doi.org/10.1007/s11999.0000000000000161.; Castelo-Branco C, Cancelo Hidalgo MJ, Palacios S, Ciria-Recasens M, Fernández-Pareja A, Carbonell-Abella C et al. Efficacy and safety of ossein-hydroxyapatite complex versus calcium carbonate to prevent bone loss. Climacteric. 2020;23(3):252–258. https://doi.org/10.1080/13697137.2019.1685488.; Castelo-Branco C, Dávila Guardia J. Use of ossein-hydroxyapatite complex in the prevention of bone loss: a review. Climacteric. 2015;18(1):29–37. https://doi.org/10.3109/13697137.2014.929107.; Тихилов РМ, Лила АМ, Кочиш АЮ, Алексеева ЛИ, Шубняков ИИ, Денисов АО и др. Коксартроз: клинические рекомендации. М.; 2021. 71 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/666_1.; Пигарова ЕА, Рожинская ЛЯ, Белая ЖЕ, Дзеранова ЛК, Каронова ТЛ, Ильин АВ и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016;62(4):60–84. https://doi.org/10.14341/probl201662460-84.; Шавловская ОА, Сарвилина ИВ, Громова ОА, Шаров МН, Бокова ИА, Прокофьева ЮС и др. Фармакотерапия боли при заболеваниях костномышечной системы: эволюция и революция взглядов. Неврология, нейропсихиатрия, психосоматика. 2022;14(4):87–95. https://doi.org/10.14412/2074-2711-2022-4-87-95.; Сарвилина ИВ, Данилов АБ. Сравнительный анализ применения симптоматических препаратов замедленного действия, содержащих хондроитина сульфат или влияющих на его биосинтез, у пациентов с неспецифической болью пояснично-крестцовой локализации. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023;123(1):81–96. https://doi.org/10.17116/jnevro202312301181.; Филатова ЮС, Соловьев ИН. Некоторые аспекты противовоспалительной терапии остеоартрита. Медицинский совет. 2023;(13):157–164. https://doi.org/10.21518/ms2023-251.; Qi SS, Shao ML, Sun Z, Chen SM, Hu YJ, Li XS et al. Chondroitin Sulfate Alleviates Diabetic Osteoporosis and Repairs Bone Microstructure via Anti-Oxidation, Anti-Inflammation, and Regulating Bone Metabolism. Front Endocrinol (Lausanne). 2021;12:759843. https://doi.org/10.3389/fendo.2021.759843.; https://www.med-sovet.pro/jour/article/view/8204

الاتاحة: https://www.med-sovet.pro/jour/article/view/8204
https://doi.org/10.21518/ms2024-066

المؤلفون: Yu. S. Filatova, I. N. Solovyov, A. M. Gruzdev, Ю. С. Филатова, И. Н. Соловьев, А. М. Груздев

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2023); 152-158 ; Медицинский Совет; № 21 (2023); 152-158 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: эффективность терапии, hip joints, hyaluronic acid preparations, administration of the drug under ultrasound control, effectiveness of therapy, тазобедренные суставы, препараты гиалуроновой кислоты, введение препарата под контролем УЗИ

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7943/7055; Scheuing WJ, Reginato AM, Deeb M, Acer Kasman S. The burden of osteoarthritis: Is it a rising problem? Best Pract Res Clin Rheumatol. 2023:101836. https://doi.org/10.1016/j.berh.2023.101836.; Molnar V, Matišić V, Kodvanj I, Bjelica R, Jeleč Ž, Hudetz D et al. Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. Int J Mol Sci. 2021;22(17):9208. https://doi.org/10.3390/ijms22179208.; Fioravanti A, Tenti S, Cheleschi S. Editorial: Year 2020: New Trends in Pharmacological Treatments for Osteoarthritis. Front Pharmacol. 2022;13:892934. https://doi.org/10.3389/fphar.2022.892934.; Ganz R, Parvizi J, Beck M, Leunig M, Nötzli H, Siebenrock KA. Femoroacetabular impingement: a cause for osteoarthritis of the hip. Clin Orthop Relat Res. 2003;(417):112–120. https://doi.org/10.1097/01.blo.0000096804.78689.c2.; Ganz R, Leunig M, Leunig-Ganz K, Harris WH. The etiology of osteoarthritis of the hip: an integrated mechanical concept. Clin Orthop Relat Res. 2008;466(2):264–272. https://doi.org/10.1007/s11999-007-0060-z.; Matsumoto K, Ganz R, Khanduja V. The history of femoroacetabular impingement. Bone Joint Res. 2020;9(9):572–577. https://doi.org/10.1302/2046-3758.99.BJR-2020-0003.; Lespasio MJ, Sultan AA, Piuzzi NS, Khlopas A, Husni ME, Muschler GF, Mont MA. Hip Osteoarthritis: A Primer. Perm J. 2018;22(1):17-084. https://doi.org/10.7812/TPP/17-084.; Sandiford N. Kendoff D, Muirhead-Allwood S. Osteoarthritis of the hip: aetiology, pathophysiology and current aspects of management. Ann Jt. 2019;5:8. https://doi.org/10.21037/aoj.2019.10.06.; Van Berkel AC, Schiphof D, Waarsing JH, Runhaar J, van Ochten JM, Bindels PJE, Bierma-Zeinstra SMA. Course of pain and fluctuations in pain related to suspected early hip osteoarthritis: the CHECK study. Fam Pract. 2022;39(6):1041–1048. https://doi.org/10.1093/fampra/cmac030.; Bothner H, Wik O. Rheology of hyaluronate. Acta Otolaryngol. 1987;104(Suppl. 442):25–30. https://doi.org/10.3109/00016488709102834.; Wang CT, Lin YT, Chiang BL, Lin YH, Hou SM. High molecular weight hyaluronic acid down-regulates the gene expression of osteoarthritis-associated cytokines and enzymes in fibroblast-like synoviocytes from patients with early osteoarthritis. Osteoarthritis Cartilage. 2006;14(12):1237–1247. https://doi.org/10.1016/j.joca.2006.05.009.; Yasuda T. Hyaluronan inhibits prostaglandin E2 production via CD44 in U937 human macrophages. Tohoku J Exp Med. 2010;220(3):229–235. https://doi.org/10.1620/tjem.220.229.; Sasaki A, Sasaki K, Konttinen YT, Santavirta S, Takahara M, Takei H et al. Hyaluronate inhibits the interleukin-1beta-induced expression of matrix metalloproteinase (MMP)-1 and MMP-3 in human synovial cells. Tohoku J Exp Med. 2004;204(2):99–107. https://doi.org/10.1620/tjem.204.99.; Тихилов РМ, Лила АМ, Кочиш АЮ, Алексеева ЛИ, Шубняков ИИ, Денисов АО. Коксартроз: клинические рекомендации. М.; 2021. 71 с. Режим доступа: https://cr.minzdrav.gov.ru/recomend/666_1.; Clementi D, D’Ambrosi R, Bertocco P, Bucci MS, Cardile C, Ragni P et al. Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study. Eur J Orthop Surg Traumatol. 2018;28(5):915–922. https://doi.org/10.1007/s00590-017-2083-9.; Migliore A, Tormenta S, Laganà B, Piscitelli P, Granata M, Bizzi E et al. Safety of intra-articular hip injection of hyaluronic acid products by ultrasound guidance: an open study from ANTIAGE register. Eur Rev Med Pharmacol Sci. 2013;17(13):1752–1759. Available at: https://www.europeanreview.org/article/4552.; Eymard F, Maillet B, Lellouche H, Mellac-Ducamp S, Brocq O, Loeuille D et al. Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study. BMC Musculoskelet Disord. 2017;18(1):3. https://doi.org/10.1186/s12891-016-1359-2.; Koyano G, Jinno T, Koga D, Hoshino C, Okawa A. Intra-articular Injections of Cross-linked Hyaluronic Acid in Japanese Patients with Symptomatic Osteoarthritis of the Hip. Prog Rehabil Med. 2021;6:20210038. https://doi.org/10.2490/prm.20210038.; Migliore A, Frediani B, Gigliucci G, Foti C, Crimaldi S, De Lucia O, Iolascon G. Efficacy of a Single Intra-Articular HYMOVIS ONE Injection for Managing Symptomatic Hip Osteoarthritis: A 12-Month Follow-Up Retrospective Analysis of the ANTIAGE Register Data. Orthop Res Rev. 2020;12:19–26. https://doi.org/10.2147/ORR.S239355.; Pogliacomi F, Schiavi P, Paraskevopoulos A, Leigheb M, Pedrazzini A, Ceccarelli F, Vaienti E. When is indicated viscosupplementation in hip osteoarthritis? Acta Biomed. 2018;90(Suppl. 1):67–74. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503407/.; Migliore A, Massafra U, Bizzi E, Vacca F, Martin-Martin S, Granata M et al. Comparative, double-blind, controlled study of intra-articular hyaluronic acid (Hyalubrix) injections versus local anesthetic in osteoarthritis of the hip. Arthritis Res Ther. 2009;11(6):R183. https://doi.org/10.1186/ar2875.; Ye Y, Zhou X, Mao S, Zhang J, Lin B. Platelet rich plasma versus hyaluronic acid in patients with hip osteoarthritis: A meta-analysis of randomized controlled trials. Int J Surg. 2018;53:279–287. https://doi.org/10.1016/j.ijsu.2018.03.078.; Abate M, Scuccimarra T, Vanni D, Pantalone A, Salini V. Femoroacetabular impingement: is hyaluronic acid effective? Knee Surg Sports Traumatol Arthrosc. 2014;22(4):889–892. https://doi.org/10.1007/s00167-013-2581-1.; Lee YK, Lee GY, Lee JW, Lee E, Kang HS. Intra-Articular Injections in Patients with Femoroacetabular Impingement: a Prospective, Randomized, Double-blind, Cross-over Study. J Korean Med Sci. 2016;31(11):1822–1827. https://doi.org/10.3346/jkms.2016.31.11.1822.; Conrozier T, Monfort J, Chevalier X, Raman R, Richette P, Diraçoglù D et al. EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis. Cartilage. 2020;11(1):47–59. https://doi.org/10.1177/1947603518783455.; Филатова ЮС, Соловьев ИН. Гиалуроновая кислота в лечении остеоартрита различных локализаций. Обзор литературы. Терапевтический архив. 2022;94(8):1014–1019. https://doi.org/10.26442/00403660.2022.08.201790.; Филатова ЮС, Гауэрт ВР. Гиалуроновая кислота при внутрисуставном введении: зависимость эффекта от молекулярной массы. РМЖ. Медицинское обозрение. 2021;5(3):156–161. https://doi.org/10.32364/2587-6821-2021-5-3-156-161.; Филатова ЮС, Соловьев ИН. Пациент с остеоартритом коленных суставов: тактика ведения в амбулаторных условиях. Медицинский совет. 2021;(2):86–93. https://doi.org/10.21518/2079-701X-2021-2-86-93.; https://www.med-sovet.pro/jour/article/view/7943

الاتاحة: https://www.med-sovet.pro/jour/article/view/7943
https://doi.org/10.21518/ms2023-407

المؤلفون: Yu. S. Filatova, I. N. Solovyov, Ю. С. Филатова, И. Н. Соловьев

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2023); 157-164 ; Медицинский Совет; № 13 (2023); 157-164 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: нимесулид, osteoarthritis pain, osteoarthritis therapy, nonsteroidal anti-inflammatory drugs, nimesulide, боль при остеоартрите, терапия остеоартрита, нестероидные противовоспалительные препараты

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7724/6859; Hunter D.J., Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182): 1745–1759. https://doi.org/10.1016/S0140-6736(19)30417-9.; Quicke J.G., Conaghan P.G., Corp N., Peat G. Osteoarthritis year in review 2021: epidemiology & therapy. Osteoarthritis Cartilage. 2022;30(2):196–206. https://doi.org/10.1016/j.joca.2021.10.003.; Long H., Liu Q., Yin H., Wang K., Diao N., Zhang Y. et al. Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74(7):1172–1183. https://doi.org/10.1002/art.42089.; Allen K.D., Thoma L.M., Golightly Y.M. Epidemiology of osteoarthritis. Osteoarthritis Cartilage. 2022;30(2):184–195. https://doi.org/10.1016/j.joca.2021.04.020.; Molnar V., Matišić V., Kodvanj I., Bjelica R., Jeleč Ž., Hudetz D. et. Al Cytokines and Chemokines Involved in Osteoarthritis Pathogenesis. Int J Mol Sci. 2021;22(17):9208. https://doi.org/10.3390/ijms22179208.; Fioravanti A., Tenti S., Cheleschi S. Editorial: Year 2020: New Trends in Pharmacological Treatments for Osteoarthritis. Front Pharmacol. 2022;13:892934. https://doi.org/10.3389/fphar.2022.892934.; Abramoff B., Caldera F.E. Osteoarthritis: Pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104(2):293–311. https://doi.org/10.1016/j.mcna.2019.10.007.; Fioravanti A., Tenti S., McAllister M., Chemaly M., Eakin A., McLaughlin J. et al. Exploring the Involvement of NLRP3 and IL-1β in Osteoarthritis of the Hand: Results from a Pilot Study. Mediators Inflamm. 2019;2019:2363460. https://doi.org/10.1155/2019/2363460.; Salaffi F., Ciapetti A., Carotti M. The sources of pain in osteoarthritis: A pathophysiological review. Reumatismo. 2014;66(1):57–71. https://doi.org/10.4081/reumatismo.2014.766.; Zhang Y., Nevitt M., Niu J., Lewis C., Torner J., Guermazi A. et al. Fluctuation of knee pain and changes in bone marrow lesions, effusions, and synovitis on magnetic resonance imaging. Arthritis Rheum. 2011;63(3):691–699. https://doi.org/10.1002/art.30148.; Morgan M., Thai J., Nazemian V., Song R., Ivanusic J.J. Changes to the activity and sensitivity of nerves innervating subchondral bone contribute to pain in late-stage osteoarthritis. Pain. 2022;163(2):390–402. https://doi.org/10.1097/j.pain.0000000000002355.; Zhu S., Zhu J., Zhen G., Hu Y., An S., Li Y. et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. J Clin Investig. 2019;129(3):1076–1093. https://doi.org/10.1172/JCI121561.; Belluzzi E., Stocco E., Pozzuoli A., Granzotto M., Porzionato A., Vettor R. et al. Contribution of infrapatellar fat pad and synovial membrane to knee osteoarthritis pain. Biomed Res Int. 2019;2019:6390182. https://doi.org/10.1155/2019/6390182.; Belluzzi E., Macchi V., Fontanella C.G., Carniel E.L., Olivotto E., Filardo G. et al. Infrapatellar fat pad gene expression and protein production in patients with and without osteoarthritis. Int J Mol Sci. 2020;21(17):6016. https://doi.org/10.3390/ijms21176016.; Yu H., Huang T., Lu W.W., Tong L., Chen D. Osteoarthritis Pain. Int J Mol Sci. 2022;23(9):4642. https://doi.org/10.3390/ijms23094642.; Yao Q., Wu X., Tao C., Gong W., Chen M., Qu M. et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):56. https://doi.org/10.1038/s41392-023-01330-w.; Katz J.N., Arant K.R., Loeser R.F. Diagnosis and treatment of hip and knee osteoarthritis: A review. JAMA. 2021;325(6):568–578. https://doi.org/10.1001/jama.2020.22171.; Richard M.J., Driban J.B., McAlindon T.E. Pharmaceutical treatment of osteoarthritis. Osteoarthritis Cartilage. 2023;31(4):458–466. https://doi.org/10.1016/j.joca.2022.11.005.; Oo W.M., Yu S.P., Daniel M.S., Hunter D.J. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs. 2018;23(4):331–347. https://doi.org/10.1080/14728214.2018.1547706.; Филатова Ю.С., Ильин М.В., Соловьев И.Н. Остеоартрит: современные возможности терапии. Амбулаторная хирургия. 2022;(1):60–67. https://doi.org/10.21518/1995-1477-2022-19-1-60-67.; Kolasinski S.L., Neogi T., Hochberg M.C., Oatis C., Guyatt G., Block J. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149–162. https://doi.org/10.1002/acr.24131.; Kloppenburg M., Kroon F.P., Blanco F.J., Doherty M., Dziedzic K.S., Greibrokk E. et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16–24. https://doi.org/10.1136/annrheumdis-2018-213826.; Bannuru R.R., Osani M.C., Vaysbrot E.E., Arden N.K., Bennell K. et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. https://doi.org/10.1016/j.joca.2019.06.011.; Лила А.М., Мазуров В.И., Мартынов А.И., Загородний Н.В., Алексеева Л.И., Чичасова Н.В. и др. Резолюция консенсуса экспертов Российской Федерации по диагностике и лечению остеоартрита 2022. Современная ревматология. 2022;(6):106–116. https://doi.org/10.14412/1996-7012-2022-6-106-116.; da Costa B.R., Reichenbach S., Keller N., Nartey L., Wandel S., Jüni P., Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090):e21–e33. https://doi.org/10.1016/S0140-6736(17)31744-0.; Osani M.C., Vaysbrot E.E., Zhou M., McAlindon T.E., Bannuru R.R. Duration of Symptom Relief and Early Trajectory of Adverse Events for Oral Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020;72(5):641–651. https://doi.org/10.1002/acr.23884.; Ton J., Perry D., Thomas B., Allan G.M., Lindblad A.J., McCormack J. et al. PEER umbrella systematic review of systematic reviews: Management of osteoarthritis in primary care. Can Fam Physician. 2020;66(3):e89–e98. Available at: https://pubmed.ncbi.nlm.nih.gov/32165479.; Wongrakpanich S., Wongrakpanich A., Melhado K., Rangaswami J. A Comprehen sive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018;9(1):143–150. https://doi.org/10.14336/AD.2017.0306.; Sostres C., Gargallo C.J., Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;(Suppl. 3):S3. https://doi.org/10.1186/ar4175.; Honvo G., Leclercq V., Geerinck A., Thomas T., Veronese N., Charles A. et al. Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(1):45–64. https://doi.org/10.1007/s40266-019-00661-0.; Насонов Е.Л. Эффективность и переносимость нестероидного противовоспалительного препарата. Нимесулид: новые данные. РМЖ. 2001;(15): 636–638. Режим доступа: https://www.rmj.ru/articles/revmatologiya/Effektivnosty_i_perenosimosty_nesteroidnogo_protivovospalitelynogo_preparata_Nimesulid_novye_dannye/#.; Camu F., Shi L., Vanlersberghe C. The role of COX-2 inhibitors in pain modulation. Drugs. 2003;63(1):1–7. https://doi.org/10.2165/00003495200363001-00002.; Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.A. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA. 1999;96(13):7563–7568. https://doi.org/10.1073/pnas.96.13.7563.; Magni E. The effect of nimesulide on prostanoid formation. Drugs. 1993;46(1):10–14. https://doi.org/10.2165/00003495-199300461-00004.; Davis R., Brogden R.N. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1994;48(3):431–454. https://doi.org/10.2165/00003495-199300461-00004.; Shaik M.S., Chatterjee A., Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma. Clin Cancer Res. 2004;10(4):1521–1529. https://doi.org/10.1158/1078-0432.ccr-0902-03.; Liang M., Yang H., Fu J. Nimesulide inhibits IFNgamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms. Cancer Lett. 2009;276(1): 47–52. https://doi.org/10.1016/j.canlet.2008.10.028.; Afzal M., Bhardwaj D.P., Khan R., Kazmi I., Saleem S., Al-Abbasi F.A., Anwar F. Antineoplastic influence of nimesulide in chemically induced hepatocellular carcinoma by inhibition of DNA synthesis. Inflammopharmacology. 2019;27(1):89–98. https://doi.org/10.1007/s10787-018-0481-1.; Candelario-Jalil E. Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences. Pharmacol Res. 2008;57(4):266–273. https://doi.org/10.1016/j.phrs.2008.03.003; Zanjani T.M., Sabetkasaei M., Karimian B., Labibi F., Farokhi B., Mossafa N. The attenuation of pain behaviour and serum interleukin-6 concentration by nimesulide in a rat model of neuropathic pain. Scand J Pain. 2010;1(4):229–234. https://doi.org/10.1016/j.sjpain.2010.08.003.; Золотовская И.А., Давыдкин И.Л. Когнитивно-цитокиновый эффект нестероидных противовоспалительных препаратов в терапии больных пожилого возраста с остеоартрозом. Успехи геронтологии. 2017;(3):381–389. Режим доступа: http://www.gersociety.ru/netcat_files/userfiles/10/AG_2017-30-03.pdf.; Vunnam N., Young M.C., Liao E.E., Lo C.H., Huber E., Been M. et. al. Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAILinduced apoptosis by promoting DR5 clustering. Cancer Biol Ther. 2023;24(1):2176692. https://doi.org/10.1080/15384047.2023.2176692.; Catarro M., Serrano J.L., Ramos S.S., Silvestre S., Almeida P. Nimesulide Analogues: From Anti-Inflammatory to Antitumor Agents. Bioorg Chem. 2019;88:102966. https://doi.org/10.1016/j.bioorg.2019.102966.; Caiazzo E., Ialenti A., Cicala C. The Relatively Selective Cyclooxygenase-2 Inhibitor Nimesulide: What’s Going on? Eur J Pharmacol. 2019;848:105–111. https://doi.org/10.1016/j.ejphar.2019.01.044.; Uram Ł., Filipowicz-Rachwał A., Misiorek M., Winiarz A., Wałajtys-Rode E., Wołowiec S. Synthesis and Different Effects of Biotinylated PAMAM G3 Dendrimer Substituted With Nimesulide in Human Normal Fibroblasts and Squamous Carcinoma Cells. Biomolecules. 2019;9(9):437. https://doi.org/10.3390/biom9090437.; Suleyman H., Cadirci E., Albayrak A., Halici Z. Nimesulide is a Selective COX-2 Inhibitory, Atypical Non-Steroidal Anti-Inflammatory Drug. Curr Med Chem. 2008;15(3):278–283. https://doi.org/10.2174/092986708783497247.; Sengel-Turk C.T., Hascicek C., Bakar F., Simsek E. Comparative Evaluation of Nimesulide-Loaded Nanoparticles for Anticancer Activity Against Breast Cancer Cells. AAPS PharmSciTech. 2017;18(2):393–403. https://doi.org/10.1208/s12249-016-0514-2.; Nam K.T., Hahm K.B., Oh S.Y., Yeo M., Han S.U., Ahn B. et al. The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter Pylori-Associated Gastric Cancer Development in a Mouse Model. Clin Cancer Res. 2004;10(23):8105–8113. https://doi.org/10.1158/1078-0432.CCR-04-0896.; Chu M., Wang T., Sun A., Chen Y. Nimesulide Inhibits Proliferation and Induces Apoptosis of Pancreatic Cancer Cells by Enhancing Expression of PTEN. Exp Ther Med. 2018;16(1):370–376. https://doi.org/10.3892/etm.2018.6191.; Ferreira R.G., Narvaez L.E.M., Espíndola K.M.M., Rosario A.C.R.S., Lima W.G.N., Monteiro M.C. Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer? Front Oncol. 2021;11:594917. https://doi.org/10.3389/fonc.2021.594917.; Mattia C., Ciarcia S., Muhindo A., Coluzzi F. Nimesulide: 25 years later. Minerva Med. 2010;101(4):285–293. Available at: https://pubmed.ncbi.nlm.nih.gov/21030939.; Rainsford K.D. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006;22(6):1161–1170. https://doi.org/10.1185/030079906X104849.; Kress H.G., Baltov A., Basiński A., Berghea F., Castellsague J., Codreanu C. et. аl. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin. 2016;32(1):23–36. https://doi.org/10.1185/03007995.2015.1100986.; Fossaluzza V., Montagnani G. Efficacy and tolerability of nimesulide in elderly patients with osteoarthritis: double-blind trial versus naproxen. J Int Med Res. 1989;17(3):295–303. https://doi.org/10.1177/030006058901700313.; Fioravanti A., Storri L., Di Martino S., Bisogno S., Oldani V., Scotti A., Marcolongo R. A randomized, double-blind, multicenter trial of nimesulide-beta-cyclodextrin versus naproxen in patients with osteoarthritis. Clin Ther. 2002;24(4):504–519. https://doi.org/10.1016/s0149-2918(02)85127-x.; Kriegel W., Korff K.J., Ehrlich J.C., Lehnhardt K., Macciocchi A., Moresino C., Pawlowski C. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract. 2001;55(8):510–514. Available at: https://pubmed.ncbi.nlm.nih.gov/11695069.; Алексеева Л.И., Каратеев А.Е., Попкова Т.В., Новикова Д.С., Шарапова Е.П., Маркелова Е.П., Насонов Е.Л. Эффективность и безопасность длительного применения нимесулида у больных остеоартрозом: результаты 12-месячного открытого контролируемого исследования ДИНАМО (Длительное Использование Нимесулида при Артрозе Многофакторная Оценка). Научно-практическая ревматология. 2009;(4):64–72. Режим доступа: https://elibrary.ru/item.asp?id=20343992.; Wober W., Rahlfs V.W., Büchl N., Grässle A., Macciocchi A. Comparative efficacy and safety of the non-steroidal anti-inflammatory drugs nimesulide and diclofenac in patients with acute subdeltoid bursitis and bicipital tendinitis. Int J Clin Pract. 1998;52(3):169–175. Available at: https://pubmed.ncbi.nlm.nih.gov/9684433/.; Huskisson E.C., Macciocchi A., Rahlfs V., Bernstein R.M., Bremner A.D., Doyle D.V. et al. Nimesulide versus diclofenac in the treatment of osteoarthritis of the hip or knee: An active controlled equivalence study. Curr Ther Res. 1999;60:253–265. https://doi.org/10.1016/S0011-393X(99)80002-2.; Pohjolainen T., Jekunen A., Autio L., Vuorela H. Treatment of acute low back pain with the COX–2–selective anti–inflammatory drug nimesulide: results of a randomized, double–blind comparative trial versus ibuprofen. Spine. 2000;25(12):1579–1585. https://doi.org/10.1097/00007632-200006150-00019.; Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract. 2004;(144):27–32. https://doi.org/10.1111/j.1742-1241.2004.027_e.x.; Conforti A., Leone R., Moretti U., Mozzo F., Velo G. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081–1090. https://doi.org/10.2165/00002018-200124140-00006.; Данилов А.Б. Алгоритм выбора лекарственной формы нестероидного противовоспалительного препарата. Лечащий врач. 2010;(7):74 Режим доступа: https://www.lvrach.ru/2010/07/15081982.; Combe B., Vélicitat P., Garzón N., Bluhmki E. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001;50(1):10–16. https://doi.org/10.1007/PL00022374.; Neighbor M.L., Puntillo K.A. Intramuscular ketorolac vs oral ibuprofen in emergency department patients with acute pain. Acad Emerg Med. 1998;5(2):92–93. https://doi.org/10.1007/PL00022374.; Shrestha M., Morgan D.L., Moreden J.M., Singh R., Nelson M., Hayes J.E. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med. 1995;26(6):682–686. https://doi.org/10.1016/s0196-0644(95)70037-4.; Tramèr M.R., Williams J.E., Carroll D., Wiffen P.J., Moore R.A., McQuay H.J. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anaesthesiol Scand. 1998;42(1):71–79. https://doi.org/10.1111/j.1399-6576.1998.tb05083.x.; Atkinson T.J., Fudin J. Nonsteroidal Antiinflammatory Drugs for Acute and Chronic Pain. Phys Med Rehabil Clin N Am. 2020;31(2):219–231. https://doi.org/10.1016/j.pmr.2020.01.002.10.; Gupta A., Bah M. NSAIDs in the Treatment of Postoperative Pain. Curr Pain Headache Rep. 2016;20(11):62. https://doi.org/10.1007/s11916-016-0591-7.; Shatsky М. Evidence for the use of intramuscular injections in outpatient practice. Fam Physician. 2009;79(4):297–300. Available at: https://pubmed.ncbi.nlm.nih.gov/19235496.; Dougados M., Listrat V., Duchesne L., Amor B. Comparative efficacy of ketoprofen related to the route of administration (intramuscular or per os). A double-blind study versus placebo in rheumatoid arthritis. Rev Rhum Mal Osteoartic. 1992;59(11):769–773. Available at: https://pubmed.ncbi.nlm.nih.gov/1306600.; Kim C., Armstrong M.J., Berta W.B., Gagliardi A.R. How to identify, incorporate and report patient preferences in clinical guidelines: A scoping review. Health Expect. 2020;23(5):1028–1036. https://doi.org/10.1111/hex.13099.; Дмитриева Е.В., Егорова С.Н. Твердые пероральные лекарственные формы: изучение потребительских предпочтений пациентов (на примере антигипертензивных препаратов). Медицинский альманах. 2010;(4):67–70. Режим доступа: https://www.elibrary.ru/item.asp?id=15321050.; https://www.med-sovet.pro/jour/article/view/7724

الاتاحة: https://www.med-sovet.pro/jour/article/view/7724
https://doi.org/10.21518/ms2023-251